STS101 Use Reduces Migraine Frequency Over Time 

STS101 (Dihydroergotamine Nasal Powder) Shows Benefit on the Resolution of Cardinal Migraine Symptoms Photophobia, Phonophobia, and Nausea: Results From the Long-Term Phase 3 Open-Label ASCEND Study 

Dihydroergotamine (DHE) Plasma Concentration and Clinical Response Relationship: An In-Office PK/PD Study 

CYP3A4 Inhibitor Itraconazole Does Not Cause Clinically Relevant Interactions With STS101 (Dihydroergotamine Nasal Powder) 

Dihydroergotamine for migraine: Evidence for multiple modes of action: The single molecule ‘combination’ product—A narrative review

Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study

Long-Term Safety and Tolerability Data of STS101 From the Phase 3 Open-Label ASCEND Study

STS101 Demonstrated Long-Term Clinical Benefit in the Phase 3 Open-Label ASCEND Study

STS101 (Dihydroergotamine Nasal Powder) Shows Long Duration Anti-Migraine Benefit on Baseline Photophobia,Phonophobia, and Nausea: Results From the Phase 3 Double-Blind, Randomized, Placebo-Controlled SUMMIT Study

STS101 (Dihydroergotamine Nasal Powder) Shows Pain Relief in Difficult to Treat Migraine Attacks: Results From the Phase 3 Double-blind, Randomized, Placebo-controlled SUMMIT Study